Summary
Apolipoprotein measurements have been applied to the estimation of coronary risk in patients and also to the characterization of various kinds of dyslipidemia, where apolipoprotein profiles are altered in a significant way. The concentration of apolipoprotein B is increased in various types of primary and secondary dyslipidemia including: Type II, III and V primary dyslipidemia, chronic renal failure and Type I, insulin-dependent diabetes. Apo AI concentrations are decreased in Type I, II B and IV dyslipidemia, as well as in liver disease. Apo E is increased in Type III and V dyslipidemia.
The combination of apolipoproteins and lipids quantitation enables a better discrimination between different kinds of dyslipidemia and the choice of an appropriate dietary or drug treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Brown MS, Goldstein JL, Fredrickson DS (1983) Familial type 3 hyperlipoproteinemia (dyslipoproteinemia). In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS (eds) The metabolic basis of inherited disease, 5th edn. McGraw-Hill, New York, 299: 1421–1424
De Backer G, Hulstaert F, De Munck K, Rosseneu M, Van Parijs L, Dramaix M (1986) Serum lipids and apoproteins in students whose parents suffered prematurely from a myocardial infarction. Am Heart J 112: 478–484
De Backer G, Rosseneu M, Deslypere JP (1982) Discriminative value of lipids and apoproteins in coronary heart disease. Atherosclerosis 42: 197–203
Freedman DS, Srinivasan SR, Shear CL, Franklin FA, Webber LS, Berenson GS (1986) The relation of apolipoproteins AI and B in children to parental myocardial infarction. N Engl J Med 315: 721–726
Fredrickson DS, Levy RI, Lees RS (1967) Fat transport in lipoproteins: an integrated approach to mechanisms and disorders. N Engl J Med 276: 273–281
Goldstein JL, Brown MS (1982) The LDL receptor defect in familial hypercholesterolemia. Implication for pathogenesis and therapy. Med Clin North Am 66: 335–362
Havel RJ (1982) Familial dysbetalipoproteinemia. New aspects of pathogenesis and diagnosis. Med Clin North Am 66: 441–454
Heiss G, Tyroler HA (1983) Are apolipoproteins useful for evaluating ischemic heart disease? A brief overview of the literature. In: Lippel K (ed) Proceedings of the workshop on apolipoprotein quantification. NIH Publication No. 83–1266, Bethesda, pp 7–24
Herbert PN, Assmann G, Gotto AM, Fredrickson DS (1983) Familial lipoprotein deficiency: abetalipoproteinemia, hypobetalipoproteinemia, and Tangier disease. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS (eds) The metabolic basis of inherited disease, 5th edn. McGraw-Hill, New York, pp 589–621
Leitersdorf E, Gottehrer N, Fainaru M, Friedlander Y, Friedman G, Tzivoni D, Stein G (1986) Analysis of risk factors in 532 survivors of first myocardial infarction hospitalized in Jerusalem. Atherosclerosis 59: 75–93
Muls E, Blaton V, Rosseneu M, Lesaffre E, Lamberigts G, De Moor P (1982) Serum lipids and apolipoproteins AI, All and B in hyperthyroidism before and after treatment. J Clin Endocrinol Metab 55: 459–464
Muls E, Rosseneu M, Blaton V, Lesaffre E, Lamberigts G, De Moor P (1984) Serum lipids and apolipoproteins AI, All and B in primary hypothyroidism before and during treatment. Eur J Clin Invest 14: 12–15
Riesen WF, Mordasini R, Salzmann C, Theler A, Ourtner HP (1980) Apolipoproteins and lipids as discriminators of severity of coronary heart disease. Atherosclerosis 37: 157–162
Rosseneu M, Bury J (1988) Apolipoprotein assays for the diagnosis of hyperlipidemias. Impact on Prevention of Atherosclerotic Diseases: 143–154
Rosseneu M, De Backer G, Caster H, Hulstaert F, Burj J (1987) Distribution and composition of HDL subclasses in students whose parents suffered prematurely from a myocardial infarction in comparison with controls. Atherosclerosis 63: 231–235
Rosseneu M and Van Biervliet JP (1985) Screening and follow-up of infants with dyslipoproteinemia. In: Widhalm K, Naito H (eds) Detection and treatment of lipid and lipoprotein disorders in childhood. AR Liss, New York, pp 79–86
Schaefer EJ (1987) Clinical biochemical and genetic features in familial disorders of high density lipoprotein deficiency. Atherosclerosis 4: 303–315
Sedlis SP, Schechtman KB, Ludbrook PA, Sobel BE, Schonfeld G (1986) Plasma apoproteins and the severity of coronary artery disease. Circulation 73: 978–986
Sniderman AD, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich PO (1980) Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human plasma low density lipoproteins). Proc Natl Acad Sci (USA) 77: 604–608
Van Biervliet JP, Vinaimont N, Caster H, Rosseneu M (1982) A screening procedure for dyslipoproteinemia in newborns. Apoprotein quantitation on dried-blood spots. Clin Chim Acta 120: 191–200
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag/Wien
About this chapter
Cite this chapter
Rosseneu, M. (1991). Clinical significance of apolipoprotein measurements. In: Rosseneu, M., Widhalm, K., Jarausch, J. (eds) Apolipoproteins in Lipid Disorders. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9148-4_2
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9148-4_2
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82273-9
Online ISBN: 978-3-7091-9148-4
eBook Packages: Springer Book Archive